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dSchool of Physics and Astronomy, Nottingh
† Electronic supplementary informatio
procedures and experimental data. See DO
Cite this: RSC Adv., 2021, 11, 6346
Received 27th December 2020
Accepted 18th January 2021
DOI: 10.1039/d0ra10859f
rsc.li/rsc-advances
6346 | RSC Adv., 2021, 11, 6346–635e to bioactive carbon dots: a light-
up probe for bioimaging investigations, glucose
detection and potential immunotherapy agent for
melanoma skin cancer†
Frederico Hillesheim Horst,a Carime Vitória da Silva Rodrigues,*b
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Bioactive carbon dots (C-dots) with ca. 4 nm were successfully produced with singular photophysical
properties, low-toxicity and interesting immunological response. The optical properties of the C-dots
were investigated and the “light-up” behaviour enabled them to be explored in glucose detection and
bioimaging experiments (mitochondrial selective probe). C-dots were not selective to the tumour region
and several fluorescent spots were visualized spread on animal bodies. The histology investigations
showed that cancer-bearing mice treated with C-dots presented a large number of regions with
necrosis and inflammatory infiltrates, which were not identified for cancer-bearing mice without the
treatment. These results suggested that C-dots have the potential to be explored as an immune therapy
agent for melanoma skin cancer.Introduction
Cancer is a general term for a group of diseases characterized by
the disorderly spread and growth of defective cells. It can be
detected in any part of the body and its mortality rate is globally
increasing. Those diseases are expected to be the major cause of
death in the 21st century.
Nanotechnology has been an important allied on ghting
cancer.1,2 The versatility of nanomaterials in cancer therapy has
contributed for recent innovations in drug delivery systems and
enabled the creation of new therapeutic agents based on
particle surface functionalization with molecules and biomol-
ecules (nucleic acid strands, peptides, proteins or antibodies).3,4
These sophisticated multifunctional nanosystems can
contribute to more precise diagnostics and less invasive
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It is well-known that compounds containing boronic acid-
groups can be widely used in the diagnostic and treatment of
different pathologies.5–8 Several reports have described these
compounds as selective taggants of glycoproteins, inhibitors of
virus and bacterias, immunopotentiators and/or imunosensiti-
zation agents of tumour cells.9,10 Boronic acid group can form
highly-stable cyclic esters with cis-1,2 and 1,3-Lewis base
molecules (alcohol and amine) in biological media. This
important characteristic enabled the development of specic
enzyme inhibitors that can be used for Alzheimer's disease and
cancer treatments.11–13 For instance, the peptidylboronic anti-
neoplastic agent Bortezomib has been used in cancer treatment
since 2003.14
Phenylboronic acid (PBA) belongs to a class of organic
ligands that are widely employed for molecular recognition.
Reports have indicated that PBA can target and reduce the
proliferation process of prostate and breast cancer cells.15,16 In
vivo investigations demonstrated the effectiveness of nano-
particles coated with boronic groups in prolonging the survival
time of cancer-bearing mice and reducing tumour growth.16,17
PBA derivatives can also mimic the recognition properties of the
lectins for tagging sugar fragments on cell surface.14 Liu and co-
workers produced a PBA-containing polymer which can revers-
ibly capture and release cancer cells depending on the pH and
glucose concentration.18 In another example, Deshayes and co-


































































































View Article Onlinefragments and a parent complex of the anticancer drug oxali-
platin was able to reduce the growth rate of both orthotopic and
lung metastasis models of melanoma in vivo.13
Recent studies have demonstrated that malignant cell
transformation, tumour growth, metastasis and the pessimistic
prognosis in some cancer patients have been directly associated
with the hypersialylation of the plasmatic cell membrane.19
Aberrant Sialic Acid (SA) overexpression protects the cancer cell
against immune recognition and eradication, and facilitates
migration and tissue invasion.20 Galvan and co-workers have
conrmed the correlation between the SA levels and the
progression of malignant melanoma in 25 patients.21 In accor-
dance with this study, patients in advanced melanoma stages
presented high levels of SA in comparison with those in the
early stage. Antibody and lectins have been widely explored for
proling the hyperexpression of SA onto the cell surface, while
other strategies appeal for recombinant and SA-bind proteins
for detecting anomalies in sialy glycans on cells and tissues.22
However, these biomolecule-based strategies, that normally are
expensive and very time-consuming, require complicated
methods and costly equipments.
Cancer treatment based on boronic acid containing mole-
cules have been widely reported.17 For instance, Plopper and
co-workers demonstrated that PBA is selective and effective to
reduce viability and migration of prostate and breast cancer
cells.23 In another in vitro and in vivo investigation, PBA
inhibited 57% of endocarcinoma 4T1 growth aer intra-
peritoneal administration in mice.12 Nagasaki and co-
workers reported a PBA-decorated polymeric nanoparticle
that is effective against a B16 melanoma-bearing mice
model.24
Among the nanomaterials used against cancer, a new class of
material has recently emerged and is showing promising
results, that is, the carbon dots (C-dots).25–27 C-dots are sphe-
roidal nanoparticles with sizes typically smaller than 10 nm,
composed by a graphitic core and covered by an amorphous
carbonaceous edge.25,28 C-dots modied with PBA moieties can
present outstanding selectivity for glycoproteins andScheme 1 Schematic approach adopted for production of PBAC-dots.
© 2021 The Author(s). Published by the Royal Society of Chemistryantineoplastic properties that make them interesting nano-
platforms for the development of theragnostic tools.29,30 Based
on our interest in the development of optical probes with more
selective properties and cancer treatment, this work presents
the synthesis, characterization and biological investigation of
a simple luminescent platform based on surface-modied C-
dots with PBA (PBAC-dots). We also report the exploration of
PBAC-dots as a light-up probe for saccharide, bioimaging agent
and a potential immunotherapy agent for melanoma skin
cancer.Results and discussion
The production and passivation of C-dots were performed in
accordance with our previous work using cow manure or
glucose as the carbon sources.31 4-Formylphenylboronic acid (4-
FPBA) was covalently bonded to primary amines of the passiv-
ated C-dots by Schiff base formation followed a reduction with
sodium borohydride (see Scheme 1).
Fig. 1 shows high-resolution HRTEM images and particle
size distributions acquired of the PBAC-dots. The spheroidal
PBAC-dots are well-dispersed and presented narrow size
distribution ranging from 2–6 nm with average diameter of
4.2 nm  0.032 nm. Fig. 1(a) exhibits a representative HRTEM
image of an individual particle. PBAC-dots presents high crys-
talline structure with lattice parameter of 2.2 Å, which agrees
well with [100] lattice spacing of graphene along the [001]
diffraction plane.32
The XPS spectrum of the PBAC-dots (Fig. 1(c)) clearly
displays ve elements, O, N, C, S and B, and their contents are
39.10%, 4.11%, 48.00%, 3.45% and 5.42%, respectively. The
presence of boron onto PBAC-dots surface indicates that PBA
moieties were successfully introduced in the synthesis process.
The high-resolution XPS spectra are available in ESI.† C 1s
spectrum presents three peaks at 289.4, 286.6 and 285.3 eV
which can be assigned to the C]O, C]C and C–C bonds,
respectively (Fig. S1(a)†). Fig. S1(b)† is the O 1s line that shows
peaks at 532.4, 533.62 and 535.6 eV related to –C]O, C–O andRSC Adv., 2021, 11, 6346–6352 | 6347
Fig. 1 (a) HRTEM image of the PBAC-dots; (b) particle size distribu-
tion; (c) XPS full-scan spectrum of PBAC-dots; (d) IR spectrum of
PBAC-dots.
Fig. 2 (a) Absorption (Abs) and emission (Emis) spectra acquired at
room temperature of C-dot-NH2 (black) and PBAC-dots (blue); (b)
normalized emission spectra as function of excitation wavelength of
PBAC-dots; (c) emission spectra as function of glucose concentration
of PBAC-dots; (d) linear plot of integrated emission as function of
glucose concentration. I0 and I are the integrated emission spectra of


































































































View Article Online–B–O groups, respectively. The N 1s peak centred at 402 eV
(Fig. S1(c)†) may be attributed to (C)3–N (sp
3). The B 1s spectra,
displayed at Fig. S1(d),† show three peaks centred at 194.5,
191.7 and 188.3 eV, which are clearly ascribed to the B–O2, B–O
and B–C bonds, respectively. The infrared spectrum of the
PBAC-dots (Fig. 1(d)) corroborates with the XPS spectroscopy
analysis, since it shows characteristic peaks of B–O stretching
vibration at 1378 cm1, B–O–H bending vibrations at 1160 and
1030 cm1, and C–B stretching at 1090 cm1.
Surface-engineering with functional ligands plays an
important role endowing nanoparticles for biomedical appli-
cations, since these modications can contribute to the
improvement of their optical and magnetic properties, solvent
affinity, biocompatibility and nontoxicity.33 In addition, these
functional surface agents corroborate for increasing the speci-
city, tuning the kinetics of the nanoparticles in biological
environments, and enhancing colloidal stability. The optical
properties of the C-dot are especially sensible to minimal
surface modications. Recent reports have conrmed that the
presence of electron-donor or withdrawing groups, pH, solvent
molecules, ions and surface defects, can perturb electronic
structure over the nanoparticle surface.34–36 Electronic effects of
modied PBAC-dots were investigated by means of optical
spectroscopy. The luminescent properties of the PBAC-dots are
exhibited in Fig. 2.
The UV-Vis absorption spectra, measured for C-dot-NH2 and
PBAC-dots, show bands centred at 280 and 284 nm, respectively.
These absorptions are typical of n/ p* transitions and provide
evidence that the presence of withdrawing groups onto PBAC-
dots surface slightly reduces the band gap energy.32,37,38 The
normalized emission spectra of the C-dot-NH2 and PBAC-dots
acquired at room temperature with excitation at 360 nm,
Fig. 2(a), exhibit maxima centred at 450 and 475 nm, respec-
tively. These results suggest that the optical properties of C-dot-
NH2 and PBAC-dots are not entirely controlled by the quantum
connement effect and the different behaviours can be attrib-
uted to the surface functionalization. The excitation-dependent6348 | RSC Adv., 2021, 11, 6346–6352emissions (Fig. 2(b)) suggest the presence of different emissive
states onto PBAC-dots surface. Remarkably, this spectral
behaviour has been widely reported for C-dots obtained from
distinct carbon sources and synthetic methods. C-dots structure
consists of a crystalline graphitic core covered by an amorphous
carbon structure, which are embedded by heterogeneous pop-
ulation of uorophores. These uorophores can be responsible
for the typical excitation-dependent emission spectra.39
Interest in boronic-acid-functionalized C-dots has soared in
recent years concomitant to the huge evolution of glycobiology
and its implications in treatments and diagnostics of severe
pathologies. Production of boronic-containing C-dots is cheap,
fast and can be rapidly performed in a unique step via hydro-
thermal or microwave synthesis. Several groups have produced
and explored these optical probes as a non-enzymatic approach
for saccharides detection in different environments.40–43 Xu and
co-workers obtained a boronic-containing optical probe for
detection of sialic acid in aqueous solution, using the sole
precursor 3-pyridylboronic acid in a one-step hydrothermal
synthesis.44 Phenylboronic acid and ethylenediamine were used
to produce functionalized C-dots for detecting glycoproteins.45
It is important to note that the examples mentioned above are
selective, reproductive and presented good detection limits.
However, in all cases, the probes responses are associated with
luminescence quenching. This “turn-off” effect on C-dot emis-
sions is not clear. Some studies have justied that quenching
occurs due to particle aggregations.42,45,46 Boron hybridization
changes and/or the presence of nonradiative channels induced
by electrostatic forces—aggregation/disaggregation caused by
the anionic form of the boronic acid upon analyte complexation
is another possible mechanism for the quenching.47 The lack of


































































































View Article Onlinehow it affects luminescence indicates an open eld for further
investigations.
Usually, “light-down” probes might be inaccurate in sensing
and might have limited work environment. On the other hand,
“light-up” sensors are normally preferred due to their enhanced
sensing capacity, especially in biological medium where the
background uorescence is highly problematic. Fig. 2(c)
displays the emission intensity of PBAC-dots as a function of
glucose concentration. Binding with glucose enhances emis-
sion intensities up to 6-fold relative to PBAC-dots and presents
a good linear relationship (R2¼ 0.998) as shown in Fig. 2(d). The
presence of an electron-donor group in the chemical structure
of boronic acid derivatives is well-established as a cornerstone
for the design of “light-up” sensors.48,49 Therefore, the antago-
nist behaviour presented by PBAC-dots in presence of glucose
does not arise from a simple accident or haphazard. In fact, this
emerges from a previous stratagem used in boronic acid
derivatives.48–51 In general, surface functionalization of nano-
particles is one of the most important limiting factors for
biomedical applications, because it affects the cytotoxic prop-
erties, the dynamic of cell uptake and selectivity.52,53Fig. 3 MCF-7 breast cancer cells incubated with PBAC-dots and
visualized on both the green and red channels. (A)–(C) Live cells. (D)
and (E) Adhered cells. No staining could be detected inside the nuclei
of the cells as shown by dark voids (N). (C) and (F) show the normal
morphological aspects of the cells by phase contrast microscopy.
© 2021 The Author(s). Published by the Royal Society of ChemistryThe performance of PBAC-dots probe in in vitro bioimaging
experiments was also evaluated using MCF-7 cells (Fig. 3).
PBAC-dots displayed an intense uorescent signal in confocal
microscope at both green and red channels. In addition, no
cytotoxicity evidence was observed. MTT assays obtained also
for other cell lines (Fig. S2†) showed no deleterious effect.
The uorescent prole obtained in cells aer PBAC-dots
incubation indicates selective mitochondrial staining (Fig. 3). It
is noteworthy to mention the fact that PBAC-dots were not
found inside the nuclei of the cells, contrasting with previous
results from C-dots passivated exclusively with ethylenediamine
(C-dot-NH2),31 which were selective to nucleoli acid components
inside the nuclei. Many works have depicted that C-dots are in
general noncytotoxic and can be easily internalized by the cell.54
However, Havrdova and co-workers demonstrated the toxicity-
dependence of C-dots as function of surface charge.55 In this
study, negatively charged C-dots have shown almost no cyto-
toxicity for high concentrations (0.1 mg mL1). Cytotoxicity of
PBAC-dots on melanoma (B16F10) and broblast (NIH3T3)
murine cells was evaluated in three different concentrations
(0.01, 0.05 and 0.1 mg mL1) during 24 h, and aerwards MTT
assays were performed to evaluate the cell viability. The only
concentration that showed signicant toxicity was 0.1 mg mL1
for B16F10 and NIH3T3 cells (p < 0.01). The apparent lowFig. 4 Representative in vivo fluorescence bioimaging for anes-
thetized C57BL/6 mice (a) control; (b) non-tumour mice acquired 4 h
after administration of PBAC-dots (0.16 mg mL1); (c) melanoma-
bearing mice 4 days after tumour induction and 4 h after administra-
tion of PBAC-dots (0.16 mg mL1); (d) melanoma-bearing mice 8 days
after tumour induction and 4 h after administration of PBAC-dots
(0.16 mg mL1); (e) melanoma-bearing mice 14 days after tumour
induction and 4 h after administration of PBAC-dots (0.16 mg mL1).
White circles indicate fluorescence on dorsal regions. White arrows
emphasize fluorescence on the kidney region. White triangles indicate
the fluorescence in ureter regions and black circles indicate the
tumour region.


































































































View Article Onlinecytotoxicity of PBAC-dots can be justied by the presence of
negative surface charges centred at boronic groups at physio-
logical pH.56
The “light-up” characteristic of PBAC-dots and the high
complexing affinity at pH 7.4 between the boronic and sialic
acid groups open up the opportunity to explore this nanoprobe
as a tumour imaging agent using in vivo models.18,56 It is well-
known that melanoma murine B16F10 cells are tremendously
aggressive, canmetastasize from a primary subcutaneous site to
the lungs and present high levels of sialic acid expressed on
their membrane.57 Hence, to validate the feasibility of the in vivo
bioimaging probe, experiments on skin cancer-bearing mice
were conducted. All animal procedures were performed in
accordance with the Guidelines for Care and Use of Laboratory
Animals of University of Brasilia (UnB) and experiments were
approved by the Animal Ethics Committee of UnB. The subcu-
taneous injection of 105 B16F10 cells resulted in tumour growth
at the injection site. Fluorescence bioimaging of C57BL/6 mice
can be seen in Fig. 4.
All C57BL/6 mice treated with PBAC-dots presented several
uorescent spots spread all along animal bodies. The bio-
imaging of healthy C57BL/6 mice treated with PBAC-dots was
used as control as shown in Fig. 4(a). It was possible to observe
the uorescence on the kidneys and ureter regions, which is
a clear indication of the PBAC-dots excretion via the urinary
system. Licciardello and co-workers found that carbon
quantum dots had been mainly eliminated by kidneys aer 60
minutes of their application.58 The histological studies
demonstrated no abnormalities on brain, kidney, spleen, lung
and liver tissues, such as necrosis, apoptosis or haemorrhageFig. 5 Histological images of the brains, lungs, livers, spleens and
kidneys of the control and cancer-bearing mice treated with PBAC-
dots.
6350 | RSC Adv., 2021, 11, 6346–6352(see Fig. 5(b)). Haematological and serum biochemistry assays
are in good agreement with the histological result since they did
not show evidence of toxicological disturbances in healthy mice
treated with PBAC-dots (Fig. S28–S30†).
The bioimages of the cancer-bearing mice acquired 4 h aer
PBAC-dots administration (0.16 mg mL1), Fig. 4(c)–(e), show
a dispersive uorescent pattern suggesting that the probe is not
selective to the tumour region. Other in vivo uorescent images
acquired aer 2, 6, 24 and 48 h of 0.16 and 0.32 mg mL1
administrations of PBAC-dots presented the same behaviour
and are available in Fig. S3–S26.† It was possible to observe
luminescent spots on kidney and ureter regions.
The histopathological images of the organs are shown in
Fig. 5. The studies demonstrated no evidence of tissue damage
on the brain and kidneys for all cancer-bearing mice treated
with PBAC-dots, whereas inammatory focus and white pulp
hyperplasia were observed in liver and spleen tissues, respec-
tively. On lung tissue, there are areas of brosis and inam-
matory inltrate.
Fig. 6 shows the histological analysis of the tumour tissues.
Surprisingly, aer the treatment with PBAC-dots a large number
of areas of necrosis and inammatory inltrate were revealed,
which were not identied for cancer-bearing mice without the
treatment (Fig. 6(b)–(d)).
Similar results were reported when C-dots and graphene-
oxide were used in photodynamic therapy,59,60 however, PBAC-
dots were able to introduce tumour lesion without external
stimulus. Haematological assays were also used to shed light on
this astonishing therapeutic effect of the PBAC-dots. The major
haematological parameters are similar to those presented by
the control group, except for the number of white blood cells in
cancer-bearing mice whose blood samples were collected 30
days aer PBAC-dots administration. This alteration can be
interpreted as a response of immunological system for theFig. 6 Histological images of the tumour. (a) Cancer-bearing mice
without PBAC-dots treatment. Histological images of the tumour-
bearing mice treated 0.16 mg mL1 of PBAC-dots after 4 (b), 8 (c) and
14 (d) days of cancer induction. The “n’ indicates necrosis regions, red
and black arrows indicate intact tumoral tissue and Immunological
cells, respectively.


































































































View Article Onlinehigher cancer stage, since previous reports have demonstrated
that C-dots presented non toxicological effects on haemato-
logical parameters aer 28 days of treatment.60 Lymphogram
results showed a growth of lymphocyte percentage for cancer-
bearing mice euthanized 2 and 30 days aer treatment,
(Fig. S28†). Therefore, PBAC-dots can either interact with the
tumour and stimulate the immune system to respond more
strongly against the disease, or can interfere indirectly on
cancer cells abilities to keep themselves undetectable by the
immune system.61 Both hypotheses are plausible for explaining
the lesion on the tumour.
Bortezomib (Velcade) is a kind of dipeptide boronic acid that
acts as a proteasome inhibitor and was approved by the U.S.
Food and Drug Administration (FDA) for use in therapies for
a myriad of cancers. The boronic group of the Bortezomib is
associated with the protease inhibition that contributes to
sensitizing solid tumours to T-cell-mediated killing, stabilizing
T-cell activation, and thus improving the outcome of adoptive T-
cell therapy of cancer.62–65 Tumour cells are apparently more
susceptible to proteasome inhibition than normal cells caused
by the loss of checkpoint mechanisms that occurs during
tumorigenesis. Bortezomib and PBAC-dots have the boronic
acid group incorporated in their structures, thus allowing us to
highlight the importance of this acid to the observed outcomes.
The results presented in this work also indicate the potential of
PBAC-dots as checkpoint inhibitor.
Mechanistic knowledge of the cancer sensitization induced
by PBAC-dots is vital for expanding its application in different
cancers and pathologies, however, for that, it would be required
more specic studies on a molecular level base.
Conclusions
In summary, it was demonstrated that the strategy adopted to
modify the C-dots surface with PBA moieties resulted in
a nontoxic light-up probe for glucose detection in aqueous
solution, that was well tolerated by mice. It was also determined
that PBAC-dots can induce necrosis in tumour tissues in cancer-
bearing mice. Cell imaging experiments indicated the prefer-
ence for mitochondria and it could be visualized in both green
and red channels. The haematological studies showed a signif-
icative increase of lymphocyte that can be associated with
immunological stimulation. Future works will be focused on
elucidating the antitumoral mechanism of PBAC-dots.
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